He has contributed significantly to the development of imatinib for the treatment of CML and successfully pioneered an ALK+ lymphoma patient therapy with ALK inhibitors. His research centers on identifying the molecular pathogenesis of hematological cancers using genome sequencing. He is interested in molecular mechanisms governing the transition from chronic phase to blast crisis in CML. In addition he is engaged in target validation of oncogenic fusion genes, structural characterization and screening of small-molecule inhibitors and new tyrosine kinase inhibitors to overcome therapy resistance in patients with ALK+ lymphomas.